Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lantus vs NPH-insulin Duration of Action in T2D
NCT00553020Phase 4Completed
- Sponsor
- Sanofi
- Start
- Apr 2004
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, single-blind trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Duration of metabolic effect. Started Apr 2004; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00553020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553020.